ABSTRACT
Purpose Pathological complete response (pathCR) in rectal cancer, seen in examination of the pathological specimen post-surgery is the phenomenon whereby a tumour completely regresses under treatment with chemoradiotherapy. This is beneficial as up to 75% of patients do not experience regrowth of the primary tumour, allowing organ preservation and is poorly understood. We aimed to characterise the processes involved in pathCR.
Materials & Methods Two groups of patients were identified with either complete response (pathCR group) or no response (poor response group) and biopsy and/or resection specimen blocks were retrieved. These underwent high read depth amplicon sequencing, exome sequencing, methylation arrays and immunohistochemistry for DNA repair pathway proteins. Sequencing data underwent analysis and the two cohorts were compared.
Results Seven patients who underwent pathological complete response and twenty four who underwent poor response (to act as opposite “extreme phenotypes”) underwent molecular characterisation. Patients in the complete response group had significantly higher tumour mutational burden, neoantigen load and enrichments for mutations in the PI3K/AKT/mTOR signalling pathway as well as significantly lower numbers of structural variants. There were no differences in copy number variants or tumour heterogeneity. Methylation analysis demonstrated enrichment for changes in the PI3K/AKT/mTOR signalling pathway.
Conclusions The phenomenon of pathCR in rectal cancer appears to be related to immunovisibility caused by a high tumour mutational burden phenotype. Resistance mechanisms seem to involve the PI3K/AKT/mTOR signalling pathway and tumour heterogeneity does not seem to play a role in resistance.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by grants from the Academy of Medical Sciences and the Wellcome Trust (ref 102732/Z/13/Z). ADB is currently supported by a Cancer Research UK Advanced Clinician Scientist award (ref C31641/A23923)
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This study was supported by grants from the Academy of Medical Sciences and the Wellcome Trust (ref 102732/Z/13/Z). ADB is currently supported by a Cancer Research UK Advanced Clinician Scientist award (ref C31641/A23923)
Statistical analysis: Andrew Beggs (a.beggs{at}bham.ac.uk)
Conflicts of interest: The authors declare no conflict of interest
Data sharing statement: All sequence data will be uploaded to the SRA archive on publication of this study. All methylation microarray data will be uploaded to the GEO archive on publication of this study.
Data Availability
Sequencing data will be uploaded to EGA on acceptance of the manuscript